Rejected from JCI? The 7 Best Journals to Submit Next

• Disease mechanism at the molecular level: JCI wants to know how diseases work. Not just that a treatment works, but why. Not just that a gene is associated with disease, but what the gene does in the disease process. The mechanistic explanation is the paper.

• Clinical relevance that's direct, not speculative: "This pathway could potentially be targeted therapeutically" isn't enough. JCI wants patient data, clinical cohort validation, or at minimum a clear translational trajectory that connects your mechanism to an identifiable clinical need.

• Breadth across disease biology: JCI publishes across all diseases: immunology, metabolism, cardiovascular, oncology, neurology, infectious disease. Your paper needs to interest disease biologists beyond your narrow specialty.

• "The mechanism is interesting but the disease connection is weak.": You showed a molecular pathway in cell lines without connecting it to a human disease. JCI needs the disease bridge.

• "The clinical data are strong but the mechanism is already known.": You showed a treatment works, but the biology of why is established. JCI wants new mechanistic insight, not clinical confirmation of known pathways.

• "The work is too specialized for JCI's broad readership.": Your paper advances understanding of one specific disease, but the principle doesn't generalize. JCI wants disease mechanisms that teach broader lessons about biology.

Before choosing your next journal, a JCI manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• Too basic for JCI?: Try a basic science journal (Cell, EMBO Journal, Molecular Cell) that values mechanism without requiring the disease bridge.

• Too clinical for JCI?: Try a clinical journal (NEJM, The Lancet, JAMA) that values outcomes without requiring the mechanism.

• Right niche, not impactful enough?: JCI Insight is the most natural cascade. EMBO Molecular Medicine is the European alternative.

• Rejected after review?: Fix concerns and try JEM or Nature Medicine. JCI academic editors overlap with these journals' reviewer pools.

JCI Insight is the companion journal to JCI, published by the same organization (ASCI). It publishes high-quality biomedical research that falls below JCI's impact threshold but is still scientifically strong. The acceptance rate (~20%) is more realistic, and the editorial culture is familiar. If JCI offered a transfer to JCI Insight, take it seriously. The transfer preserves your editorial history and reviewer connections.

Best for: Disease mechanism papers that are solid but didn't clear JCI's impact bar. Clinical cohort studies with mechanistic components.

JEM has a long tradition in immunology and disease biology. The journal values experimental rigor and mechanistic depth. If JCI rejected your paper for being "too immunological" or "too focused on one disease pathway," JEM may value that focused depth.

Best for: Immunological disease mechanisms, infectious disease biology, tumor immunology, autoimmune mechanisms.

For papers where the translational component is stronger than the mechanistic component, Nature Medicine may be a better fit than JCI. Nature Medicine wants work at the biology-clinical interface, and it values therapeutic discovery alongside mechanism.

Best for: Translational research with therapeutic implications, biomarker discovery, precision medicine, clinical discovery with biological insight.

EMBO Molecular Medicine publishes molecular mechanisms of disease with a European editorial perspective. If JCI found your paper "too molecular" or "too focused on one pathway," EMBO Molecular Medicine may value that molecular depth.

Best for: Molecular disease mechanisms, particularly in European research contexts.

DMM (published by The Company of Biologists) focuses on in vivo disease models. If your paper's primary contribution is a new disease model or a mechanistic finding in an animal model, DMM provides a specialized audience.

Best for: Animal models of human disease, in vivo disease mechanism studies, model organism disease biology.

For biomedical papers that are clearly good science but don't fit JCI's specific disease-mechanism mandate, Nature Communications provides a broad-scope home.

Best for: Solid biomedical research that fell below JCI's impact bar. Interdisciplinary disease research.

PNAS publishes biomedical research across all disease areas. The journal values rigor and completeness without requiring the disease-mechanism narrative JCI demands. Strengthen the disease connection. If JCI said the disease relevance was insufficient, don't add a single paragraph about "potential clinical implications." Either include patient data, clinical cohort validation, or therapeutic relevance experiments, or submit to a basic science journal that doesn't require the clinical bridge.

Best for: Rigorous biomedical research, disease biology, therapeutic mechanism studies.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.

In our pre-submission review work with manuscripts targeting the Journal of Clinical Investigation, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Disease connection too weak or speculative. JCI's academic editors are working scientists with deep disease-area expertise, which means their desk rejections are precise scope judgments rather than superficial reads. We see this failure consistently in manuscripts we review: papers demonstrating a molecular mechanism in cell lines or animal models where the connection to a specific human disease process is either missing or framed as a speculative "future therapeutic direction." In our review of JCI submissions, we find that editors consistently require the human disease bridge to be demonstrated with patient data or clinical cohort validation, not inferred.

Mechanism already established in prior publications. JCI publishes work that reveals how diseases work at the molecular level, not work that validates what the mechanism literature already shows. We see this pattern in translational submissions we review targeting JCI present clinical efficacy or observational data for a pathway whose mechanism was characterized by other groups in prior publications. Editors consistently redirect these papers to clinical journals.

Disease biology too specialized for JCI's cross-disease readership. JCI covers immunology, metabolism, cardiovascular biology, oncology, neurology, and infectious disease in a single readership. Papers advancing understanding of one specific disease without a broader mechanistic lesson that disease biologists outside the subfield would find instructive consistently fail the breadth test at JCI's desk.

Preclinical mechanism with no clear translational trajectory. Identifying a new kinase target in a mouse model of autoimmune disease without demonstrating the target's relevance in human samples or identifying a clinical path forward generates consistent desk returns. JCI editors require that the distance from mechanism to patient implication be direct, not speculative.

SciRev community data for the Journal of Clinical Investigation confirms desk rejections typically arrive within days, consistent with the fast editorial process JCI's academic editor model maintains.

Think twice before submitting to Nature Medicine if JCI's reviewers identified gaps in disease-context validation; Nature Medicine's translational bar is high and the same concerns will surface.